Development of a Reversible Vas Deferens Occlusion Device. VII. Physical and Microscopic Observations after Long-Term Implantation of Flexible Prosthetic Devices

Brueschke, Erich E.; Kaleckas, Richard A.; Wingfield, James R.; Welsh, Thomas; Zaneveld, L. J. D.

doi:10.1016/s0015-0282(16)44538-3

Fertility and Sterility

1980

DOI: 10.1016/s0015-0282(16)44538-3

|View full text |Cite

Development of a Reversible Vas Deferens Occlusion Device. VII. Physical and Microscopic Observations after Long-Term Implantation of Flexible Prosthetic Devices

Erich E. Brueschke¹,

Richard A. Kaleckas²,

James R. Wingfield³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of an intravasal method for occlusion with the option of subsequent reversal is not new. Earlier attempts to develop reversible occlusive technology focused on rigid and flexible prosthetic devices (Brueschke et al, 1974a,b,c, 1975, 1979, 1980). These devices require surgical implantation, cause vasal wall erosion, and are unable to reliably occlude the vas deferens.…”

mentioning

confidence: 99%

The Use of URYX for Reversible Vasectomy in a Rabbit Model

Naughton

Myles

Thomas

2004

Journal of Andrology

View full text Add to dashboard Cite

URYX is a biocompatible polymer of ethylene vinyl alcohol dissolved in a dimethyl sulfoxide (DMSO) carrier to allow injection of a very low-viscosity fluid into tissue. Once the material comes into contact with body tissue or fluid, the DMSO rapidly dissipates from the polymer, which results in a precipitate of a coherent solid mass. The purpose of the present study was to determine whether URYX can effectively occlude the vas deferens and whether patency can be restored by redissolving the URYX in vivo using the solvent DMSO. Eight male New Zealand White rabbits (age range, 25-41 weeks; mean age, 33.9 +/- 7.5 weeks; mean weight, 4.0 +/- 0.2 kg) were used in 2 experiments (E1 and E2). In E1, 3 rabbits underwent unilateral vasectomy, and the contralateral vas was injected with either 0.05 or 0.10 mL of URYX, to determine the amount of URYX required to cause obstruction. Two animals underwent bilateral vasectomy, to serve as controls. In E2, 3 animals underwent bilateral URYX injection and were compared with the bilateral vasectomy control rabbits used in E1. After 1 month of initial bilateral URYX treatment, all animals in E2 underwent attempted unilateral reversal with 1.5 mL of DMSO injected into 1 occluded vas deferens. Two end points were evaluated-a clinical end point assessed by semen analyses and a pathological end point assessed by histological analysis of treated tissues, to assess for safety. A 1.5-cm infrapubic incision was made to expose both vasa in anesthetized rabbits. The vasal injection of URYX was performed with a 30-gauge needle. Vasectomy was performed by excision of a 1-cm segment of the vas deferens and subsequent ligation with a 6-0 prolene suture. Semen was collected using an artificial vagina 2-3 times/wk before and 1 month later, after injection treatments and vasectomy. Manual sperm counts were performed. All animals were sacrificed, and tissues (distal vas, injection site, proximal vas, cauda epididymis, caput epididymis, and testis) were harvested and examined for the presence of URYX. The inflammatory response of the wall and adventitia of the vas deferens was given a score (0-15) based on the sum of grades (0 = none, 1 = mild, 2 = moderate, and 3 = severe) for the following categories: foreign body giant cell reaction, granulation tissue, lymphocytes, eosinophils, and scarring, as evaluated by a single pathologist (J.M.). Vasal injection with 0.05 mL of URYX was not sufficient to cause occlusion. Both animals injected with 0.1 mL of URYX were effectively occluded. The injection of occluded vasa with DMSO did not dissolve the URYX plug in the vas lumen. There was no significant difference in vasal inflammatory response scores between vasal units treated with URYX only and vasal units in the vasectomy model. Vasal units subjected to URYX followed by DMSO demonstrated greater inflammatory response scores than vasal units treated with URYX followed by normal saline, URYX alone, or vasectomy. Epididymal and testicular histology remained unaffected in all vasal units in E1. The vasal units...

show abstract

mentioning

confidence: 99%

The Use of URYX for Reversible Vasectomy in a Rabbit Model

Naughton

Myles

Thomas

2004

Journal of Andrology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of a Reversible Vas Deferens Occlusion Device. VII. Physical and Microscopic Observations after Long-Term Implantation of Flexible Prosthetic Devices

Cited by 1 publication

References 2 publications

The Use of URYX for Reversible Vasectomy in a Rabbit Model

The Use of URYX for Reversible Vasectomy in a Rabbit Model

Contact Info

Product

Resources

About